SEC Tracker
Get the app

Prelude Therapeutics PRLD

Prelude Therapeutics FY 2020: net loss $56.9M

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Prelude Therapeutics reported for the year ended Dec 31, 2020, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$56.9MNo year-earlier figure tagged10-K income statement, on EDGAR
  2. Cash and cash equivalents$218.3MNo year-earlier figure tagged10-K balance sheet, on EDGAR
  3. Cash from operations−$46.2MNo year-earlier figure tagged10-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Prelude Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Edesa Biotech EDSA public float $14M, Mar 31, 2025, over 18 months old
  2. X4 Pharmaceuticals XFOR public float $15M, Jun 30, 2025
  3. Akari Therapeutics AKTX public float $15M, Jun 30, 2025
  4. GeoVax Labs GOVX public float $14M, Jun 30, 2025
  5. ProPhase Labs PRPH public float $15M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.